Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 12INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 59Thoracic 10Gynecologic 6Gastrointestinal 6Tumor-Agnostic 5CNS 5Lymphoid 4Genitourinary 4Sarcoma 3Dermatologic 3Other solid neoplasm 2Head & Neck 1

Conditions

Prostatic Neoplasms 3Urogenital Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × abemaciclib × Genitourinary × Clear all
NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting
393 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Eli Lilly and Company

Phase 1 Completed
10 enrolled
Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT04408924 2024-06-25

CYCLONE 1

Eli Lilly and Company

Phase 2 Completed
44 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡